SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ICOS Corporation

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg10/19/2006 12:37:58 AM
  Read Replies (1) of 1139
 
Icos CEO in line to receive millions from takeover

By Luke Timmerman

Seattle Times business reporter

Icos Chairman and Chief Executive Paul Clark stands to receive millions of dollars from the sale of the Bothell-based company to Eli Lilly, according to filings with the Securities and Exchange Commission.

Despite Icos' languishing stock price during the last three years, Clark was paid at the 75th percentile of industry executives, according to the company's most recent proxy statement.

In 2005, he received $4.5 million in salary, bonus, perks and awards of restricted stock.

Clark's salary and bonus accounted for $1.7 million of the package.

Under Icos' change in control plan, Clark is eligible for a cash severance payment equal to three times his annual base salary and bonus.

Clark, 59, a former pharmaceutical executive at Abbott Laboratories with an MBA, was hired in June 1999 as CEO, replacing Icos co-founder George Rathmann.

Since then, Clark has accumulated about 3 million shares and options, a 4.5 percent stake in the company.

Many of the options were awarded at prices higher than Lilly's $32-per-share offer, so the total value is not known.

But if Icos shares had appreciated at a 10 percent rate over a 10-year period from the award dates, they could have been worth up to $165 million, according to SEC filings.

Clark said the exact severance-payment figures will be disclosed soon in the company's regulatory filings.

seattletimes.nwsource.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext